The Benefits of LGD-4033 (Ligandrol) and Stanozolol (Winstrol) on Male Sexual Dimorphism and Muscular Gains
This comprehensive overview analyzes the reported beneficial effects of Ligandrol (LGD-4033) at a dose of approximately 10 mg per day and of stanozolol (Winstrol) at a dose of 10 mg per day on increases in lean muscle mass, muscle quality, strength, recovery, and morphological traits associated with male sexual dimorphism. The “Supplements” section discusses in detail complementary agents such as cardarine (GW-501516) and certain supportive compounds. The analysis is based on data from clinical trials, pharmacological studies, observational research, and secondary literature from performance-enhancement contexts.
LGD-4033 is a non-steroidal selective androgen receptor modulator (SARM) originally developed for the treatment of muscle-wasting conditions, including cachexia and sarcopenia. It binds the androgen receptor with high affinity and displays tissue selectivity that favors skeletal muscle and bone over certain reproductive tissues in preclinical models.
In the landmark Phase 1 randomized, double-blind, placebo-controlled trial conducted by Basaria et al. (2013) in 76 healthy men aged 21–50, daily oral administration of LGD-4033 at doses of 0.1 mg, 0.3 mg, or 1.0 mg for 21 days produced clear dose-dependent increases in lean body mass. At the highest dose tested (1.0 mg), participants gained a mean of 1.21 kg of lean mass relative to placebo (p = 0.047), with no statistically significant change in fat mass. The compound demonstrated a favorable pharmacokinetic profile suitable for once-daily dosing (half-life approximately 24–36 hours) and was generally well tolerated in this short-term setting. Hormone levels and lipids returned toward baseline after discontinuation.
Full study links:
At the higher doses commonly discussed in non-clinical and bodybuilding contexts (typically 5–10 mg daily for 6–10 weeks), secondary literature, case reports, and user compilations describe more substantial lean tissue gains—frequently reported in the range of several kilograms over an 8-week period—along with notable improvements in recovery between training sessions and measurable strength increases on multi-joint compound movements (bench press, squat, deadlift). The compound is consistently characterized by relatively “dry” gains, meaning limited subcutaneous water retention compared with aromatizing anabolic steroids. This contributes to a denser, more defined muscular appearance even during periods of caloric surplus. Additional reported benefits include enhanced nitrogen retention and support for muscle preservation during caloric restriction, making it relevant for both mass-building and recomposition phases.
Stanozolol is a synthetic anabolic-androgenic steroid derived from dihydrotestosterone (DHT). It features structural modifications (including a pyrazole ring fusion) that result in a reported anabolic-to-androgenic ratio of approximately 320:30. Critically, stanozolol does not undergo aromatization to estrogen, eliminating estrogen-mediated water retention and related side effects such as gynecomastia at typical doses.
At lower oral doses such as 10 mg daily, the primary reported benefits center on qualitative improvements in muscle appearance and the bioavailability of circulating androgens rather than maximal absolute mass gains. A distinctive and well-documented pharmacological action is the pronounced reduction of sex hormone-binding globulin (SHBG). In the controlled study by Sinnecker and Köhler (1989), oral stanozolol administered at 0.2 mg/kg body weight for three days reduced mean serum SHBG levels to approximately 51.6 % of baseline (a reduction of roughly 48 %) in healthy control subjects. Lower SHBG increases the free (unbound and bioavailable) fraction of testosterone and other androgens, thereby amplifying their anabolic and androgenic signaling.
Full study links:
Additional frequently cited positive effects include:
These characteristics have historically positioned stanozolol as a preferred agent for aesthetic refinement, cutting phases, and pre-contest preparation in bodybuilding and athletic contexts.
When used concurrently at the stated doses, LGD-4033 and stanozolol are reported to produce complementary and synergistic outcomes. LGD-4033 primarily drives lean mass accretion, strength increases, and recovery enhancement, while stanozolol contributes hardness, vascularity, density, and elevated free androgen availability through SHBG reduction. The net reported visual and functional result is increased muscular size and density accompanied by superior definition, limited subcutaneous water, and a more refined, athletic, “dry” physique. Progressive overload in resistance training is frequently facilitated by the combined improvements in strength and recovery capacity. Users and secondary sources often describe the combination as producing a more pronounced “enhanced” or “3D” muscular appearance compared with either compound used in isolation.
Male sexual dimorphism in body composition and physique is strongly influenced by androgen signaling acting on androgen receptors. Androgens promote greater absolute and relative skeletal muscle mass—particularly in the upper body—resulting in broader shoulders, increased deltoid, trapezius, and pectoral development, a higher shoulder-to-hip ratio (SHR), and a more pronounced V-tapered torso relative to the lower body. These morphological features rank among the most consistent visual markers of the masculine phenotype across cultures and have been linked in observational research to earlier sexual debut, higher numbers of sexual partners, greater incidence of extra-pair copulations, and elevated mate-value ratings in heterosexual contexts.
In the study by Hughes and Gallup (2003), “Sex differences in morphological predictors of sexual behavior: Shoulder to hip and waist to hip ratios,” published in Evolution and Human Behavior, male shoulder-to-hip ratio was significantly correlated with multiple measures of sexual behavior and experience.
Full study link: ScienceDirect
Androgen receptors are expressed at relatively high density in the shoulder girdle, upper trunk, and certain other sexually dimorphic muscle groups. Agents that increase androgen receptor occupancy (such as LGD-4033) or elevate free androgen levels through SHBG reduction (such as stanozolol) can therefore preferentially support hypertrophy and development in these regions. In practical terms, the lean-mass effects of LGD-4033 combined with the hardening and free-androgen elevating actions of stanozolol are frequently described in performance and aesthetic communities as accentuating upper-body dominance, shoulder width, trapezius development, and overall masculine proportions. Secondary visual refinements sometimes noted include greater visibility of muscle insertions and a more structured facial appearance secondary to reduced subcutaneous facial fat and increased underlying muscular tone, although direct controlled evidence for facial changes specifically attributable to these agents remains limited.
In performance-enhancement and aesthetic contexts, supportive compounds (ancillaries) are commonly layered alongside primary agents to enhance fat oxidation, endurance, recovery, organ support, lipid balance, and hormonal recovery while seeking to preserve or amplify the muscular and dimorphic benefits described above. The following agents and categories are frequently discussed:
Cardarine (GW-501516)A selective PPAR-δ (peroxisome proliferator-activated receptor delta) agonist originally investigated for metabolic and cardiovascular indications. It is not a SARM or anabolic steroid. Human clinical data demonstrate favorable shifts in lipid profiles. In the study by Olson et al. (2012), administration of GW-501516 produced increases in HDL cholesterol (up to approximately 16.9 % at 10 mg), along with reductions in triglycerides (up to 16.9 %), apoB, LDL cholesterol, and free fatty acids. Preclinical and limited human work also show enhanced fatty-acid oxidation in skeletal muscle and improved exercise endurance capacity (including increased running distance and a higher proportion of oxidative muscle fibers in animal models). In practical aesthetic and performance use, Cardarine is valued for supporting caloric expenditure, preserving lean tissue during deficit phases, increasing training volume tolerance, improving work capacity, and partially offsetting lipid disruptions associated with oral anabolic compounds—thereby contributing to a more conditioned, vascular, and refined appearance.
Key study links:
Other Complementary Agents
Hepatic SupportBecause oral LGD-4033 (at higher recreational doses) and oral stanozolol undergo first-pass hepatic metabolism and can be associated with elevations in liver enzymes, compounds such as N-acetylcysteine (NAC), tauroursodeoxycholic acid (TUDCA), or silymarin (milk thistle) are frequently employed to support glutathione status, bile flow, and overall hepatic resilience.
Lipid and Cardiovascular SupportStanozolol in particular can negatively affect HDL cholesterol. High-dose omega-3 fatty acids, citrus bergamot extract, or other lipid-modulating agents are commonly added to help maintain more favorable lipid parameters and support endothelial function.
Post-Cycle Therapy (PCT)Both LGD-4033 and stanozolol suppress the hypothalamic-pituitary-gonadal (HPG) axis to varying degrees. Selective estrogen receptor modulators (SERMs) such as tamoxifen or clomiphene, and in selected protocols human chorionic gonadotropin (hCG), are employed after cessation to support recovery of endogenous testosterone production and minimize post-cycle lean mass loss.
Foundational MeasuresAdequate dietary protein intake (typically elevated relative to body weight), structured progressive-resistance training optimized for progressive overload, optimized sleep hygiene, and serial laboratory monitoring (total and free testosterone, LH, FSH, comprehensive metabolic panel including liver enzymes, complete lipid panel, and hematocrit) are routinely emphasized to maximize retention of lean tissue gains, monitor physiological status, and support overall recovery.
Reported benefits of LGD-4033 at approximately 10 mg daily and stanozolol at 10 mg daily center on lean muscle accretion with limited water retention, improved muscle hardness, density, and vascularity, elevated free androgen bioavailability via SHBG reduction, enhanced recovery and strength, and accentuation of sexually dimorphic upper-body proportions (broader shoulders, higher shoulder-to-hip ratio, more pronounced V-taper, and greater upper-body muscular dominance). Complementary use of Cardarine can further support fat oxidation, endurance capacity, training volume, and lipid balance, while other ancillaries address organ support, recovery, and hormonal restoration. Clinical data are strongest for the lean-mass effects of low-dose LGD-4033 (Basaria et al., 2013) and for stanozolol’s pronounced SHBG reduction (Sinnecker & Köhler, 1989). Higher-dose recreational protocols, combination outcomes, and effects specific to the 16–21 age range remain largely extrapolated from adult trials, case reports, and non-controlled observations.
This comprehensive overview analyzes the reported beneficial effects of Ligandrol (LGD-4033) at a dose of approximately 10 mg per day and of stanozolol (Winstrol) at a dose of 10 mg per day on increases in lean muscle mass, muscle quality, strength, recovery, and morphological traits associated with male sexual dimorphism. The “Supplements” section discusses in detail complementary agents such as cardarine (GW-501516) and certain supportive compounds. The analysis is based on data from clinical trials, pharmacological studies, observational research, and secondary literature from performance-enhancement contexts.
Ligandrol (LGD-4033): Lean Mass Accretion, Strength Support, and Recovery Enhancement
LGD-4033 is a non-steroidal selective androgen receptor modulator (SARM) originally developed for the treatment of muscle-wasting conditions, including cachexia and sarcopenia. It binds the androgen receptor with high affinity and displays tissue selectivity that favors skeletal muscle and bone over certain reproductive tissues in preclinical models.
In the landmark Phase 1 randomized, double-blind, placebo-controlled trial conducted by Basaria et al. (2013) in 76 healthy men aged 21–50, daily oral administration of LGD-4033 at doses of 0.1 mg, 0.3 mg, or 1.0 mg for 21 days produced clear dose-dependent increases in lean body mass. At the highest dose tested (1.0 mg), participants gained a mean of 1.21 kg of lean mass relative to placebo (p = 0.047), with no statistically significant change in fat mass. The compound demonstrated a favorable pharmacokinetic profile suitable for once-daily dosing (half-life approximately 24–36 hours) and was generally well tolerated in this short-term setting. Hormone levels and lipids returned toward baseline after discontinuation.
Full study links:
At the higher doses commonly discussed in non-clinical and bodybuilding contexts (typically 5–10 mg daily for 6–10 weeks), secondary literature, case reports, and user compilations describe more substantial lean tissue gains—frequently reported in the range of several kilograms over an 8-week period—along with notable improvements in recovery between training sessions and measurable strength increases on multi-joint compound movements (bench press, squat, deadlift). The compound is consistently characterized by relatively “dry” gains, meaning limited subcutaneous water retention compared with aromatizing anabolic steroids. This contributes to a denser, more defined muscular appearance even during periods of caloric surplus. Additional reported benefits include enhanced nitrogen retention and support for muscle preservation during caloric restriction, making it relevant for both mass-building and recomposition phases.
Stanozolol (Winstrol): Muscle Hardness, Vascularity, Density, and Free Androgen Enhancement
Stanozolol is a synthetic anabolic-androgenic steroid derived from dihydrotestosterone (DHT). It features structural modifications (including a pyrazole ring fusion) that result in a reported anabolic-to-androgenic ratio of approximately 320:30. Critically, stanozolol does not undergo aromatization to estrogen, eliminating estrogen-mediated water retention and related side effects such as gynecomastia at typical doses.
At lower oral doses such as 10 mg daily, the primary reported benefits center on qualitative improvements in muscle appearance and the bioavailability of circulating androgens rather than maximal absolute mass gains. A distinctive and well-documented pharmacological action is the pronounced reduction of sex hormone-binding globulin (SHBG). In the controlled study by Sinnecker and Köhler (1989), oral stanozolol administered at 0.2 mg/kg body weight for three days reduced mean serum SHBG levels to approximately 51.6 % of baseline (a reduction of roughly 48 %) in healthy control subjects. Lower SHBG increases the free (unbound and bioavailable) fraction of testosterone and other androgens, thereby amplifying their anabolic and androgenic signaling.
Full study links:
Additional frequently cited positive effects include:
- Marked increases in muscle hardness, density, and “granite-like” quality due to the absence of estrogenic water retention.
- Enhanced vascularity and a more three-dimensional, chiseled appearance, particularly when body-fat levels are already in a moderate-to-low range.
- Modest lean mass retention or accretion (commonly reported in the 1.5–3 kg range of keepable tissue after longer cycles when combined with other agents).
- Strength gains often described in the 10–15 % range on major compound lifts.
- Mild stimulation of erythropoiesis (red blood cell production), which may support oxygen delivery and training capacity.
These characteristics have historically positioned stanozolol as a preferred agent for aesthetic refinement, cutting phases, and pre-contest preparation in bodybuilding and athletic contexts.
Combined Effects on Muscle Gains and Physique Quality
When used concurrently at the stated doses, LGD-4033 and stanozolol are reported to produce complementary and synergistic outcomes. LGD-4033 primarily drives lean mass accretion, strength increases, and recovery enhancement, while stanozolol contributes hardness, vascularity, density, and elevated free androgen availability through SHBG reduction. The net reported visual and functional result is increased muscular size and density accompanied by superior definition, limited subcutaneous water, and a more refined, athletic, “dry” physique. Progressive overload in resistance training is frequently facilitated by the combined improvements in strength and recovery capacity. Users and secondary sources often describe the combination as producing a more pronounced “enhanced” or “3D” muscular appearance compared with either compound used in isolation.
Effects Relevant to Male Sexual Dimorphism
Male sexual dimorphism in body composition and physique is strongly influenced by androgen signaling acting on androgen receptors. Androgens promote greater absolute and relative skeletal muscle mass—particularly in the upper body—resulting in broader shoulders, increased deltoid, trapezius, and pectoral development, a higher shoulder-to-hip ratio (SHR), and a more pronounced V-tapered torso relative to the lower body. These morphological features rank among the most consistent visual markers of the masculine phenotype across cultures and have been linked in observational research to earlier sexual debut, higher numbers of sexual partners, greater incidence of extra-pair copulations, and elevated mate-value ratings in heterosexual contexts.
In the study by Hughes and Gallup (2003), “Sex differences in morphological predictors of sexual behavior: Shoulder to hip and waist to hip ratios,” published in Evolution and Human Behavior, male shoulder-to-hip ratio was significantly correlated with multiple measures of sexual behavior and experience.
Full study link: ScienceDirect
Androgen receptors are expressed at relatively high density in the shoulder girdle, upper trunk, and certain other sexually dimorphic muscle groups. Agents that increase androgen receptor occupancy (such as LGD-4033) or elevate free androgen levels through SHBG reduction (such as stanozolol) can therefore preferentially support hypertrophy and development in these regions. In practical terms, the lean-mass effects of LGD-4033 combined with the hardening and free-androgen elevating actions of stanozolol are frequently described in performance and aesthetic communities as accentuating upper-body dominance, shoulder width, trapezius development, and overall masculine proportions. Secondary visual refinements sometimes noted include greater visibility of muscle insertions and a more structured facial appearance secondary to reduced subcutaneous facial fat and increased underlying muscular tone, although direct controlled evidence for facial changes specifically attributable to these agents remains limited.
Ancillaries and Complementary Agents
In performance-enhancement and aesthetic contexts, supportive compounds (ancillaries) are commonly layered alongside primary agents to enhance fat oxidation, endurance, recovery, organ support, lipid balance, and hormonal recovery while seeking to preserve or amplify the muscular and dimorphic benefits described above. The following agents and categories are frequently discussed:
Cardarine (GW-501516)A selective PPAR-δ (peroxisome proliferator-activated receptor delta) agonist originally investigated for metabolic and cardiovascular indications. It is not a SARM or anabolic steroid. Human clinical data demonstrate favorable shifts in lipid profiles. In the study by Olson et al. (2012), administration of GW-501516 produced increases in HDL cholesterol (up to approximately 16.9 % at 10 mg), along with reductions in triglycerides (up to 16.9 %), apoB, LDL cholesterol, and free fatty acids. Preclinical and limited human work also show enhanced fatty-acid oxidation in skeletal muscle and improved exercise endurance capacity (including increased running distance and a higher proportion of oxidative muscle fibers in animal models). In practical aesthetic and performance use, Cardarine is valued for supporting caloric expenditure, preserving lean tissue during deficit phases, increasing training volume tolerance, improving work capacity, and partially offsetting lipid disruptions associated with oral anabolic compounds—thereby contributing to a more conditioned, vascular, and refined appearance.
Key study links:
- Olson et al. (2012): PubMed | AHA Journals full text
- Sprecher et al. (2007) on HDL and triglyceride effects in healthy subjects (Arteriosclerosis, Thrombosis, and Vascular Biology).
Other Complementary Agents
- Milder SARMs such as ostarine (MK-2866 / enobosarm) for additional lean-mass support with a comparatively lower suppression profile.
- Growth-hormone secretagogues such as MK-677 (ibutamoren) for improved recovery, sleep quality, appetite stimulation, and potential synergistic effects on lean tissue.
Hepatic SupportBecause oral LGD-4033 (at higher recreational doses) and oral stanozolol undergo first-pass hepatic metabolism and can be associated with elevations in liver enzymes, compounds such as N-acetylcysteine (NAC), tauroursodeoxycholic acid (TUDCA), or silymarin (milk thistle) are frequently employed to support glutathione status, bile flow, and overall hepatic resilience.
Lipid and Cardiovascular SupportStanozolol in particular can negatively affect HDL cholesterol. High-dose omega-3 fatty acids, citrus bergamot extract, or other lipid-modulating agents are commonly added to help maintain more favorable lipid parameters and support endothelial function.
Post-Cycle Therapy (PCT)Both LGD-4033 and stanozolol suppress the hypothalamic-pituitary-gonadal (HPG) axis to varying degrees. Selective estrogen receptor modulators (SERMs) such as tamoxifen or clomiphene, and in selected protocols human chorionic gonadotropin (hCG), are employed after cessation to support recovery of endogenous testosterone production and minimize post-cycle lean mass loss.
Foundational MeasuresAdequate dietary protein intake (typically elevated relative to body weight), structured progressive-resistance training optimized for progressive overload, optimized sleep hygiene, and serial laboratory monitoring (total and free testosterone, LH, FSH, comprehensive metabolic panel including liver enzymes, complete lipid panel, and hematocrit) are routinely emphasized to maximize retention of lean tissue gains, monitor physiological status, and support overall recovery.
Summary of Reported Favorable Outcomes
Reported benefits of LGD-4033 at approximately 10 mg daily and stanozolol at 10 mg daily center on lean muscle accretion with limited water retention, improved muscle hardness, density, and vascularity, elevated free androgen bioavailability via SHBG reduction, enhanced recovery and strength, and accentuation of sexually dimorphic upper-body proportions (broader shoulders, higher shoulder-to-hip ratio, more pronounced V-taper, and greater upper-body muscular dominance). Complementary use of Cardarine can further support fat oxidation, endurance capacity, training volume, and lipid balance, while other ancillaries address organ support, recovery, and hormonal restoration. Clinical data are strongest for the lean-mass effects of low-dose LGD-4033 (Basaria et al., 2013) and for stanozolol’s pronounced SHBG reduction (Sinnecker & Köhler, 1989). Higher-dose recreational protocols, combination outcomes, and effects specific to the 16–21 age range remain largely extrapolated from adult trials, case reports, and non-controlled observations.
